Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Venous thromoboembolism is one of the most common complications in cancer patients and may have serious consequences. At present, most clinical oncologists report using thromboprophylaxis in less than 5% of patients. One of the possible reasons for this limited use is the lack of oncology specific guidelines. In effect, while there are excellent guidelines for optimising the use of antithrombotic agents to prevent and treat thromboembolism, they must be adapted to the concrete context of cancer patients. The present review explores how different situations affect cancer patients and their risk of developing venous thromboembolism (VTE), and evaluates the situations in which antithrombotic agents should be administered to treat and prevent VTE.

Original publication




Journal article


Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Publication Date





161 - 171


Servicio de Oncología Médica, Hospital General Universitario de Valencia, Valencia, Spain.


Humans, Neoplasms, Pulmonary Embolism, Hemorrhage, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Risk, Prospective Studies, Female, Male, Clinical Trials as Topic, Thromboembolism, Venous Thrombosis, Thrombophilia, Postoperative Complications, Peptide Hydrolases, Heparin, Low-Molecular-Weight, Vascular Endothelial Growth Factor A, Antithrombin III, Fibrinolytic Agents, Catheterization, Central Venous, Double-Blind Method, Immobilization